Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (9237)	10/1/2003 12:49:31 AM
From: BulbaMan	Respond to of 52153

IMHO, it's evident from the article's text that the Reuters reporter was definitely confused and even misspelled the name of the Axonyx drug (it's Phenserine). So, I wouldn't hold anything in the article against the company. With full knowledge that Phenserine is a high-odds gamble, the reason I bought a bit of AXYX stock is that I felt the $25 million in financing (with decent provisions) gave the company a reasonable amount of credibility. Given that, the risk/reward balance made it a pretty good bet.